Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting

This study has been completed.
Sponsor:
Information provided by:
Azienda Ospedaliera San Giovanni Battista
ClinicalTrials.gov Identifier:
NCT00876148
First received: April 3, 2009
Last updated: NA
Last verified: April 2009
History: No changes posted
  Purpose

The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients undergoing allografting.


Condition
Hepatitis B Virus
Allograft
Hematological Malignancies

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting

Resource links provided by NLM:


Further study details as provided by Azienda Ospedaliera San Giovanni Battista:

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

A cohort of patients undergoing allografting for hematological malignancies

Criteria

Inclusion Criteria:

  • All patients undergoing an allograft for hematological malignancies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00876148

Locations
Italy
Azienda ospedaliera S Giovanni Battista
Torino, Italy
Sponsors and Collaborators
Azienda Ospedaliera San Giovanni Battista
  More Information

No publications provided by Azienda Ospedaliera San Giovanni Battista

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00876148     History of Changes
Other Study ID Numbers: LAM Allo SCT
Study First Received: April 3, 2009
Last Updated: April 3, 2009
Health Authority: Italy: Ministry of Health

Keywords provided by Azienda Ospedaliera San Giovanni Battista:
Incidence of hepatitis B after allografting
Risk of hepatitis B reactivation
Lamivudine prophylaxis

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
DNA Virus Infections
Digestive System Diseases
Enterovirus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on November 24, 2014